Page last updated: 2024-11-06

satigrel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Satigrel: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65913
CHEMBL ID2107466
SCHEMBL ID379555
MeSH IDM0154263

Synonyms (27)

Synonym
satigrel
e-5510
e5510 ,
satigrel [inn]
5,5-bis(4-methoxyphenyl)-4-cyano-4-pentenoic acid
4-pentenoic acid, 5,5-bis(4-methoxyphenyl)-4-cyano-
4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid
ccris 7283
e 5510
4-cyano-5,5-bis(p-methoxyphenyl)-4-pentenoic acid
4-pentenoic acid, 4-cyano-5,5-bis(4-methoxyphenyl)-
4-cyano-5,5-bis(4-methoxyphenyl)pent-4-enoic acid
4-cyano-5,5-bis(4-methoxyphenyl)4-pentenoic acid
GRVCTHTXJDYIHB-UHFFFAOYSA-N
xpv71vql72 ,
unii-xpv71vql72
111753-73-2
CHEMBL2107466
SB29383330
niosh/sb2938333
satigrel [mi]
satigrel [jan]
SCHEMBL379555
DTXSID00149721
Q27293949
2-(4-fluorophenyl)-1-(4-methoxyphenyl)-1-phenylethanol
AKOS040746323

Research Excerpts

Overview

Satigrel is a new antiplatelet agent. Previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models.

ExcerptReferenceRelevance
"Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models. "( Clinical evaluation of satigrel in intermittent claudicators.
Iwai, T; Qian, S, 1996
)
2.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's18 (81.82)18.2507
2000's2 (9.09)29.6817
2010's0 (0.00)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (32.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (68.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]